What Is Inotropin and How Does It Affect the Heart?

Inotropin is a brand name for dopamine hydrochloride, a catecholamine given intravenously in intensive care units to support blood pressure and heart function during shock, severe heart failure, and other hemodynamic emergencies. Once considered a go-to vasopressor in critical care, dopamine has been largely displaced from that role by norepinephrine over the past two decades, driven by trial evidence showing higher arrhythmia rates and, in certain types of shock, higher mortality. Understanding why the medical community’s relationship with this drug changed so dramatically requires a look at how dopamine behaves at different doses, what the landmark trials actually found, and where it still has a place in modern medicine.

How Dopamine Acts on the Heart and Blood Vessels

Dopamine’s effects depend heavily on the infusion rate, and this dose-dependent behavior is central to how clinicians have used it. At low infusion rates (roughly 1 to 3 micrograms per kilogram per minute), dopamine primarily activates dopaminergic receptors in the kidneys and gut, dilating those blood vessels. At moderate rates (around 3 to 10 micrograms per kilogram per minute), it stimulates beta-1 adrenergic receptors in the heart, increasing the force of contraction (its inotropic effect) and heart rate. Push the dose higher still, and alpha-adrenergic receptor stimulation dominates, constricting blood vessels and raising blood pressure much like norepinephrine does.

That tiered pharmacology made dopamine seem versatile. A physician could, in theory, “dial in” the desired effect by adjusting the drip rate. In practice, the boundaries between these dose ranges are not as clean as textbooks suggest. Individual patients metabolize dopamine at different rates, receptor density varies, and the overlap between dose tiers means that a patient receiving a moderate dose for cardiac output may simultaneously experience unwanted vasoconstriction or tachycardia. The beta-1 adrenergic pathway that boosts contractility works through a signaling cascade involving cyclic AMP and protein kinase A, which also accelerates the heart rate and increases myocardial oxygen demand, traits shared by other catecholamine inotropes and a recurring source of side effects.

The Renal Dose Myth

For years, clinicians infused low-dose dopamine (often called “renal dose dopamine”) in critically ill patients with the hope of protecting kidney function. The logic was straightforward: dopamine dilates renal arteries at low doses, so it should increase urine output and prevent acute kidney injury. The practice became so widespread that it was nearly reflexive in many ICUs.

The evidence did not cooperate. A randomized controlled trial of 328 critically ill patients with early signs of kidney dysfunction found that low-dose dopamine provided no clinically significant protection from renal failure compared to placebo.¹ A subsequent meta-analysis reinforced this conclusion: while low-dose dopamine does transiently increase urine output, it does not prevent kidney dysfunction or reduce mortality.² The extra urine was a pharmacologic effect on the kidney tubules, not a sign of improved organ health. Renal dose dopamine is now widely regarded as an abandoned practice, though it still surfaces in some hospitals where older habits die slowly.

Dopamine Versus Norepinephrine in Shock

The most consequential blow to Inotropin’s dominance came from head-to-head trials comparing dopamine with norepinephrine as first-line vasopressors in shock. A large multicenter trial published in the New England Journal of Medicine randomized over 1,600 patients with shock to receive either dopamine or norepinephrine. The overall 28-day mortality rate did not differ significantly between the two groups (about 53% with dopamine versus 49% with norepinephrine). But dopamine was associated with roughly double the rate of arrhythmic events: 24% of dopamine patients experienced arrhythmias compared to 12% of those on norepinephrine.³

A subgroup analysis from that same trial revealed something more troubling for a specific population. Among the 280 patients with cardiogenic shock, dopamine was linked to a significantly higher death rate at 28 days compared to norepinephrine. That signal was not seen in patients with septic or hypovolemic shock, but it was strong enough to shift clinical practice.⁴ A meta-analysis focused on septic shock subsequently confirmed the trend: across randomized trials, dopamine was associated with about a 12% higher relative risk of death and more than double the risk of arrhythmias compared to norepinephrine.⁵

Why Cardiogenic Shock Is Especially Problematic

The heart in cardiogenic shock is already failing. Adding a drug that simultaneously raises heart rate, increases oxygen consumption, and triggers arrhythmias on top of that failing heart is, in hindsight, a poor match. A meta-analysis of trials in cardiogenic shock found that patients on dopamine had substantially higher 28-day mortality, a higher risk of arrhythmias (roughly threefold), and more gastrointestinal complications compared to those receiving norepinephrine.⁶ A broader review of inotropes and vasopressors in cardiogenic shock reached the same conclusion: both dopamine and adrenaline were associated with increased mortality and arrhythmias in this setting.⁷

That does not mean dopamine has vanished from ICU formularies entirely. In some settings, when norepinephrine is unavailable or a patient has significant bradycardia that might benefit from dopamine’s heart-rate-boosting properties, clinicians still reach for it. And in mechanically ventilated patients, low-dose dopamine combined with dobutamine showed some hemodynamic advantages over either drug alone in an older study: the combination maintained blood pressure better than dobutamine alone while avoiding the worsening of oxygen exchange that dopamine caused on its own.⁸ Still, these niche uses are a far cry from the drug’s former status as a first-line agent.

Arrhythmia Risk and Other Safety Concerns

The arrhythmia signal with dopamine deserves a closer look because it is not just a statistical finding buried in trial tables; it has real implications for how patients are monitored. Dopamine increases automaticity in the heart’s conduction fibers and produces greater elevations in heart rate at any given level of cardiac output improvement than dobutamine does.⁹ In a trial of septic shock patients, roughly one in five patients on dopamine developed arrhythmias, compared to about one in thirty on norepinephrine, and arrhythmia was itself identified as a predictor of death in that study.¹⁰

Beyond the heart, dopamine infusions carry a risk of tissue injury if the IV line infiltrates. Unlike some medications that simply cause local swelling when they leak out of a vein, dopamine’s vasoconstrictive properties can cause blanching, tissue death, and hematoma at the infiltration site. The damage appears related more to the duration of the leak than to the volume, which means even a small unnoticed infiltration can cause harm if it persists.¹¹ Phentolamine, an alpha-blocker, is the standard rescue agent injected locally if extravasation occurs.

When Acidosis Blunts the Drug’s Effect

Critically ill patients often develop metabolic acidosis, a drop in blood pH caused by accumulation of lactate and other acids as tissues are deprived of adequate oxygen delivery. This is precisely the situation in which clinicians are most likely to reach for an inotrope, and it is also the situation in which these drugs work least well. Research on isolated human heart muscle from patients with heart failure showed that even mild acidosis significantly impaired the response to beta-adrenergic stimulation, requiring roughly five to six times more drug to achieve the same half-maximal effect compared to normal pH conditions.¹² Animal studies confirmed that metabolic acidosis specifically dampened the inotropic response to beta-adrenergic stimulation.¹³

The practical implication is that a patient in severe shock with a pH of, say, 7.15 may not respond to dopamine or other catecholamine inotropes the way a textbook would predict. Correcting the underlying acidosis, through fluid resuscitation, source control, or bicarbonate in select cases, can restore drug responsiveness. Clinicians who keep escalating the dopamine drip without addressing the pH may be chasing a moving target while stacking up side effects.

Alternative Inotropes and Why They Matter

Part of the reason dopamine fell from favor is that alternatives emerged or were better studied. Understanding these alternatives helps explain why “inotropin” is no longer synonymous with inotropic support.

Dobutamine, a synthetic catecholamine, became the preferred inotrope for acute heart failure because it boosts cardiac output primarily through beta-1 stimulation with less of the alpha-mediated vasoconstriction and heart-rate acceleration that make dopamine troublesome. It still carries arrhythmia risk, but generally produces less tachycardia per unit of cardiac output gained than dopamine does.

Milrinone takes a different approach entirely. Rather than stimulating adrenergic receptors on the outside of the cell, it works inside the cell by blocking an enzyme called phosphodiesterase-3, which raises cyclic AMP levels independently of receptor activation. The result is both a stronger heart squeeze and dilation of peripheral blood vessels, reducing the workload on the heart.¹⁴ Because milrinone bypasses the adrenergic receptor, it can sometimes work when catecholamines fail, particularly in patients whose receptors have been desensitized by prolonged exposure to endogenous stress hormones. However, milrinone’s own effectiveness can diminish in established heart failure: studies in dogs with heart failure showed that the inotropic response to milrinone was markedly blunted compared to healthy hearts, in part because the enzyme milrinone targets is already reduced in failing myocardium.¹⁵

Levosimendan represents yet another mechanism. Instead of raising calcium levels inside the heart cell (the approach shared by catecholamines and milrinone, and the very mechanism that promotes arrhythmias), levosimendan makes the contractile machinery more sensitive to the calcium already present. It stabilizes the bond between calcium and a protein called troponin C, improving the force of contraction without the same penalty in arrhythmia risk or oxygen demand.¹⁶ Levosimendan is widely used in Europe and parts of Asia, though it has never received FDA approval in the United States.

On the experimental frontier, omecamtiv mecarbil works directly on the motor protein myosin, prolonging the time it spends in its force-generating state. Early studies in pigs, however, found a concerning tradeoff: the drug increased myocardial oxygen consumption by roughly 30% even in the unloaded heart and raised the oxygen cost of each contraction substantially, reducing overall cardiac efficiency.¹⁷ Whether this translates to clinical harm in humans remains an active area of investigation.

Negative Inotropy and Why Not All Heart Drugs Boost Contractility

While Inotropin and its relatives aim to make the heart contract harder, an entire class of commonly used cardiovascular drugs does exactly the opposite. Calcium channel blockers, prescribed for high blood pressure and certain arrhythmias, have a direct negative inotropic effect: they reduce the force of contraction, slow the heart rate, and relax blood vessel walls.¹⁸ Beta-blockers do something similar through a different route, dampening adrenergic stimulation to the heart.

This matters because patients with heart failure are often on beta-blockers for long-term survival benefit, and those same drugs blunt the response when an inotrope like dopamine is suddenly needed during an acute crisis. The heart’s beta-adrenergic receptors become downregulated over time in heart failure, and chronic beta-blocker therapy adds another layer of receptor blockade. Sustained beta-1 stimulation activates a secondary signaling pathway through a kinase called CaMKII, which partly compensates for the desensitized primary pathway, but this workaround has its own implications for arrhythmia risk.¹⁹ The interplay between chronic heart failure medications and acute inotropic rescue is one of the trickiest balancing acts in critical care.

Ambulatory Inotrope Infusions for End-Stage Heart Failure

Not all inotrope use happens during an acute emergency. Some patients with advanced, refractory heart failure who are not candidates for a heart transplant or a mechanical heart pump receive continuous inotrope infusions at home through a portable pump connected to a central venous catheter. This is palliative therapy, meant to improve quality of life and functional capacity rather than cure the underlying disease. Current guidelines acknowledge that long-term inotropes may be attempted for selected patients with end-stage heart failure who are ineligible for or choosing not to undergo transplant or device implantation.²⁰

The evidence base for ambulatory inotrope therapy remains thin. A systematic review noted that these infusions are offered without a robust understanding of relative risks and benefits, and much of the published data comes from observational studies and case series rather than randomized trials.²¹ Dobutamine and milrinone are the drugs most commonly used in this setting rather than dopamine, because they can be given through a simple continuous infusion pump and carry a somewhat more predictable side-effect profile. Patients on home inotropes require regular monitoring for arrhythmias, catheter-related infections, and signs that the heart is becoming further dependent on the drug.

Genetic Variation in Inotropic Response

One of the less discussed reasons that inotrope dosing is so unpredictable from patient to patient is genetic variation in the proteins that these drugs target. Polymorphisms in the genes encoding adrenergic receptors and the downstream signaling molecules can meaningfully alter how a person’s heart responds to catecholamine stimulation.²² A study of common variants in alpha and beta adrenoceptor genes found that specific genotypes altered hemodynamic responses to infused adrenaline in healthy young men. One variant in the alpha-2B receptor was associated with blunted coronary blood flow increases, while a variant in the beta-2 receptor changed the direction of the blood pressure response entirely: some genotypes saw diastolic pressure rise where others saw it fall.²³

Pharmacogenomic testing for inotrope response is not yet routine in clinical practice, but research in this area hints at a future where a patient’s genotype could help predict whether dopamine, dobutamine, or a non-catecholamine inotrope is the better first choice. For now, clinicians rely on real-time hemodynamic monitoring, titrating doses upward and watching for side effects, which is effective but inherently reactive rather than predictive.

Right Heart Failure and Pulmonary Hypertension

Most discussions of inotropes focus on left-sided heart failure, but the right ventricle poses its own challenges. In pulmonary arterial hypertension, the right side of the heart fails because it is pumping against abnormally high resistance in the lung vasculature. When these patients decompensate, the treatment strategy involves careful fluid management, inotropic support to improve right ventricular contractility, and drugs that dilate the pulmonary vessels to reduce the load on the right heart.²⁴ Dopamine is sometimes used in this context, but cautiously, because the alpha-mediated vasoconstriction at higher doses can worsen pulmonary pressures. Dobutamine or milrinone, which offer inotropic support with less vasoconstriction or even some vasodilation, are often preferred. The need for inotropic support in hospitalized patients with pulmonary hypertension is itself a marker of poor prognosis, underscoring the gravity of reaching for these drugs at all.